Dawson James cut shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a neutral rating in a research note issued to investors on Monday morning, FlyOnTheWall reports. Dawson James currently has $4.00 price objective on the biotechnology company’s stock. Dawson James also issued estimates for ADMA Biologics’ Q3 2019 earnings at ($0.11) EPS, Q4 2019 earnings at $0.12 EPS, FY2019 earnings at ($0.56) EPS, Q1 2020 earnings at ($0.01) EPS, FY2020 earnings at ($0.02) EPS, FY2021 earnings at $0.18 EPS, FY2022 earnings at $0.78 EPS and FY2023 earnings at $1.36 EPS.
A number of other research analysts have also recently weighed in on ADMA. HC Wainwright set a $13.00 price target on shares of ADMA Biologics and gave the company a buy rating in a research report on Thursday, May 23rd. Oppenheimer set a $14.00 price target on shares of ADMA Biologics and gave the company a buy rating in a research report on Tuesday, June 25th. Finally, Jefferies Financial Group initiated coverage on shares of ADMA Biologics in a research report on Tuesday, June 4th. They set a buy rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $10.17.
ADMA opened at $3.90 on Monday. The company’s 50 day simple moving average is $3.73 and its 200 day simple moving average is $4.03. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 2.39. ADMA Biologics has a 1 year low of $2.08 and a 1 year high of $6.96.
ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $4.36 million. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. As a group, sell-side analysts anticipate that ADMA Biologics will post -0.96 earnings per share for the current fiscal year.
In other news, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of ADMA Biologics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $3.75, for a total transaction of $21,802,327.50. Following the sale, the insider now owns 4,295,580 shares in the company, valued at $16,108,425. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 4,000,000 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were purchased at an average price of $4.00 per share, for a total transaction of $16,000,000.00. The disclosure for this purchase can be found here. Insiders own 15.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of ADMA Biologics by 0.5% in the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock valued at $2,305,000 after purchasing an additional 4,577 shares in the last quarter. Raymond James & Associates increased its holdings in shares of ADMA Biologics by 65.2% in the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of ADMA Biologics in the 4th quarter valued at about $34,000. Geode Capital Management LLC increased its holdings in shares of ADMA Biologics by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares in the last quarter. Finally, H D Vest Advisory Services increased its holdings in shares of ADMA Biologics by 35.0% in the 2nd quarter. H D Vest Advisory Services now owns 135,050 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors own 38.82% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: What is the return on assets (ROA) ratio?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.